{"organizations": [], "uuid": "28d5d26877fb906798eca53325ac18a7470c3669", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180228.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-revance-therapeutics-mylan-ireland/brief-revance-therapeutics-mylan-ireland-enter-collaboration-deal-idUSFWN1QI1ML", "country": "US", "domain_rank": 408, "title": "BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-03-01T05:26:00.000+02:00", "replies_count": 0, "uuid": "28d5d26877fb906798eca53325ac18a7470c3669"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-revance-therapeutics-mylan-ireland/brief-revance-therapeutics-mylan-ireland-enter-collaboration-deal-idUSFWN1QI1ML", "ord_in_thread": 0, "title": "BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍", "locations": [], "entities": {"persons": [], "locations": [{"name": "ireland", "sentiment": "none"}, {"name": "mylan ireland", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "revance therapeutics inc", "sentiment": "negative"}, {"name": "brief-revance therapeutics", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "mylan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 28 (Reuters) - Revance Therapeutics Inc:\n* REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​\n* REVANCE THERAPEUTICS - ‍MYLAN AGREED TO PAY CO NON-REFUNDABLE UPFRONT PAYMENT OF $25 MILLION WITH CONTINGENT PAYMENTS OF UP TO $100 MILLION\n* REVANCE THERAPEUTICS - ‍CONTINGENT PAYMENTS BASED UPON ACHIEVEMENT OF SPECIFIED MILESTONES, SPECIFIED, TIERED SALES MILESTONES OF UP TO $225 MILLION​\n* REVANCE THERAPEUTICS INC - ‍MYLAN WILL PAY REVANCE ROYALTIES ON SALES OF BIOSIMILAR IN MYLAN TERRITORIES​\n* REVANCE THERAPEUTICS - ‍MYLAN MAY ELECT TO HAVE DRUG PRODUCT MANUFACTURED BY ANOTHER PARTY\n* REVANCE THERAPEUTICS INC - CO GRANTED MYLAN EXCLUSIVE, LICENSE TO CO‘S INTELLECTUAL PROPERTY RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF BIOSIMILAR​\n* REVANCE THERAPEUTICS INC - CO WILL BE PRIMARILY RESPONSIBLE FOR NON-CLINICAL DEVELOPMENT ACTIVITIES, CLINICAL DEVELOPMENT ACTIVITIES IN N. AMERICA​ Source: ( bit.ly/2EZUJWL ) Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2EZUJWL"], "published": "2018-03-01T05:26:00.000+02:00", "crawled": "2018-03-01T20:57:31.009+02:00", "highlightTitle": ""}